5/10
08:39 am
kzr
Kezar Life Sciences, Inc. (NASDAQ: KZR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Medium
Report
Kezar Life Sciences, Inc. (NASDAQ: KZR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.